| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Experimental Therapeutics Branch, National Institute of Neurological and Communicative Disorders and Stroke, National Institutes of Health, Bethesda, MD.
Address correspondence and reprint requests to Dr. Thomas N. Chase, NINDS, NIH, Building 10 Rm 5C103, 10 Center Drive, MSC1406, Bethesda, MD 20892-1406.
Abstract.
Normal motor function is dependent on the highly regulated synthesis and release of the transmitter dopamine by neurons projecting from the substantia nigra to the corpus striatum. Parkinson's disease involves the progressive degeneration of these neurons. Its core symptoms are a direct consequence of a striatal insufficiency of intrasynaptic dopamine. Levodopa, the standard of care for the treatment of PD, acts after its conversion to dopamine by restoring striatal dopaminergic transmission. However, there are significant differences between the normally functioning dopamine system and the restoration of function provided by standard levodopa treatment. Increasing clinical and preclinical evidence suggests that the intermittent stimulation of dopamine receptors resulting from current therapeutic regimens contributes to the response complications that ultimately affect most parkinsonian patients. It now appears that chronic nonphysiologic stimulation of dopaminergic receptors on striatal GABAergic neurons activates characteristic signaling pathways, leading to a potentiation of the synaptic efficacy of adjacent glutamatergic receptors of the N-methyl-D-aspartate(NMDA) subtype. As a result, function of these GABAergic efferent neurons changes in ways that favor the appearance of motor complications. Conceivably, use of dopaminomimetic replacement strategies that provide more continuous dopamine receptor stimulation will act to prevent or alleviate these disabling complications. A number of promising approaches to achieving this goal are now under development.
This article has been cited by other articles:
|
|
 |
|
  A. Munoz, Q. Li, F. Gardoni, E. Marcello, C. Qin, T. Carlsson, D. Kirik, M. Di Luca, A. Bjorklund, E. Bezard, et al. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia Brain, December 1, 2008; 131(12): 3380 - 3394. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Xiao, E. Bastia, Y.-H. Xu, C. L. Benn, J.-H. J. Cha, T. S. Peterson, J.-F. Chen, and M. A. Schwarzschild Forebrain Adenosine A2A Receptors Contribute to L-3,4-Dihydroxyphenylalanine-Induced Dyskinesia in Hemiparkinsonian Mice J. Neurosci., December 27, 2006; 26(52): 13548 - 13555. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Caccia, R. Maj, M. Calabresi, S. Maestroni, L. Faravelli, L. Curatolo, P. Salvati, and R. G. Fariello Safinamide: from molecular targets to a new anti-Parkinson drug. Neurology, October 10, 2006; 67(7 Suppl 2): S18 - S23. [Abstract] [Full Text]
|
|
|
|
|
|
J. E. Westin, H. S. Lindgren, J. Gardi, J. R. Nyengaard, P. Brundin, P. Mohapel, and M. A. Cenci Endothelial Proliferation and Increased Blood-Brain Barrier Permeability in the Basal Ganglia in a Rat Model of 3,4-Dihydroxyphenyl-L-Alanine-Induced Dyskinesia J. Neurosci., September 13, 2006; 26(37): 9448 - 9461. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Carlsson, C. Winkler, C. Burger, N. Muzyczka, R. J. Mandel, A. Cenci, A. Bjorklund, and D. Kirik Reversal of dyskinesias in an animal model of Parkinson's disease by continuous L-DOPA delivery using rAAV vectors Brain, March 1, 2005; 128(3): 559 - 569. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Mouradian Should levodopa be infused into the duodenum? Neurology, January 25, 2005; 64(2): 182 - 183. [Full Text] [PDF]
|
|
|
|
|
|
D. G. Standaert Introduction: Adenosine A2A receptor modulation of motor systems for symptomatic therapy in Parkinson's disease Neurology, December 9, 2003; 61(90116): S30 - 31. [Full Text]
|
|
|
|
|
|
J.-F. Chen, S. Fredduzzi, E. Bastia, L. Yu, R. Moratalla, E. Ongini, and M. A. Schwarzschild Adenosine A2A receptors in neuroadaptation to repeated dopaminergic stimulation: Implications for the treatment of dyskinesias in Parkinson's disease Neurology, December 9, 2003; 61(90116): S74 - 81. [Abstract] [Full Text]
|
|
|
|
 |
|
 A. Blaukat, P. Micke, I. Kalatskaya, A. Faussner, and W. Muller-Esterl Regulation of Cardiovascular Signaling by Kinins and Products of Similar Converting Enzyme Systems: Downregulation of bradykinin B2 receptor in human fibroblasts during prolonged agonist exposure Am J Physiol Heart Circ Physiol, June 1, 2003; 284(6): H1909 - H1916. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Ahlskog Slowing Parkinson's disease progression: Recent dopamine agonist trials Neurology, February 11, 2003; 60(3): 381 - 389. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Fredduzzi, R. Moratalla, A. Monopoli, B. Cuellar, K. Xu, E. Ongini, F. Impagnatiello, M. A. Schwarzschild, and J.-F. Chen Persistent Behavioral Sensitization to Chronic L-DOPA Requires A2A Adenosine Receptors J. Neurosci., February 1, 2002; 22(3): 1054 - 1062. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Marsh and T. M Dawson Treatment of early Parkinson's disease BMJ, July 1, 2000; 321(7252): 1 - 2. [Full Text]
|
|
|
|
 |
|
 D J BROOKS Dopamine agonists: their role in the treatment of Parkinson's disease J. Neurol. Neurosurg. Psychiatry, June 1, 2000; 68(6): 685 - 689. [Full Text] [PDF]
|
|
|
|
 |
|
 O. Rascol, D. J. Brooks, A. D. Korczyn, P. P. De Deyn, C. E. Clarke, A. E. Lang, and The 056 Study Group A Five-Year Study of the Incidence of Dyskinesia in Patients with Early Parkinson's Disease Who Were Treated with Ropinirole or Levodopa N. Engl. J. Med., May 18, 2000; 342(20): 1484 - 1491. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Konitsiotis, P. J. Blanchet, L. Verhagen, E. Lamers, and T. N. Chase AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys Neurology, April 25, 2000; 54(8): 1589 - 1595. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
